According to this new data, patients on Afinitor tablets showed a significant reduction in tumour size and the absence of tumour progression. Approximately 42% of TSC patients on Afinitor had ...

Afinitor (everolimus) has been approved in the EU for advanced, progressive, non-functional neuroendocrine tumours (NETs) of gastrointestinal and lung origin and is the first oral therapy for this ...

for Everolimus tablets for oral suspension (TFOS) of strengths 2mg, 3mg and 5mg, Natco Pharma said in a regulatory filing. The drug is a generic version of AFINITOR DISPERZ by Novartis ...